{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:31:39Z","timestamp":1770744699773,"version":"3.49.0"},"reference-count":19,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2011,3,25]],"date-time":"2011-03-25T00:00:00Z","timestamp":1301011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2011,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cytokine\u2010phenotype associations have recently been described in primary myelofibrosis and increased levels of IL\u20108, sIL\u20102R, IL\u201012, and IL\u201015 were found to be independently predictive of inferior survival. Pomalidomide therapy is effective for alleviating anemia in myelofibrosis; we examined the relationship between plasma cytokine\/chemokine levels and response to treatment with pomalidomide. The study population included 32 Mayo Clinic patients (median age 66 years) who participated in two consecutive clinical trials of pomalidomide therapy for myelofibrosis\u2010associated anemia. Ten (31%) patients achieved anemia response per International Working Group criteria. Anemia response was seen only in the presence of <jats:italic>JAK2<\/jats:italic>V617F (<jats:italic>P<\/jats:italic> = 0.04) and, in addition, predicted by lower circulating levels of MCP\u20101 (<jats:italic>P<\/jats:italic> = 0.003), IL\u20102R (<jats:italic>P<\/jats:italic> = 0.008), IL\u201015 (0.01), and IL\u20108 (<jats:italic>P<\/jats:italic> = 0.02). Marked splenomegaly and increased serum LDH level were associated with poor response (<jats:italic>P<\/jats:italic> = 0.02 and 0.03, respectively) and with each other (<jats:italic>P<\/jats:italic> = 0.02), but not with <jats:italic>JAK2<\/jats:italic>V617F. The aforementioned cytokines were not significantly associated with <jats:italic>JAK2<\/jats:italic>V617F but increased levels of sIL\u20102R (<jats:italic>P<\/jats:italic> = 0.01), IL\u201015 (<jats:italic>P<\/jats:italic> = 0.06), and MCP\u20101 (<jats:italic>P<\/jats:italic> = 0.07) clustered with marked splenomegaly. Current data suggest that, in the context of pomalidomide treatment, response is more likely in the presence of <jats:italic>JAK2<\/jats:italic>V617F and further predicted by the absence of marked splenomegaly or increased levels of proinflammatory cytokines. Am. J. Hematol. 86:343\u2013345, 2011. \u00a9 2011 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ajh.21972","type":"journal-article","created":{"date-parts":[[2011,1,5]],"date-time":"2011-01-05T16:41:27Z","timestamp":1294245687000},"page":"343-345","source":"Crossref","is-referenced-by-count":26,"title":["Circulating levels of MCP\u20101, sIL\u20102R, IL\u201015, and IL\u20108 predict anemia response to pomalidomide therapy in myelofibrosis"],"prefix":"10.1002","volume":"86","author":[{"given":"Animesh","family":"Pardanani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kebede","family":"Begna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christy","family":"Finke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terra","family":"Lasho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,3,25]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200004273421706"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V51.2.189.189"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb04970.x"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.11.4369"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1913"},{"key":"e_1_2_5_7_2","doi-asserted-by":"crossref","first-page":"691","DOI":"10.4049\/jimmunol.160.2.691","article-title":"Adenovector\u2010mediated expression of human thrombopoietin cDNA in immune\u2010compromised mice: Insights into the pathophysiology of osteomyelofibrosis","volume":"160","author":"Frey BM","year":"1998","journal-title":"J Immunol"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.4.2271"},{"key":"e_1_2_5_9_2","article-title":"Circulating IL\u20108, IL\u20102R, IL\u201012, and IL\u201015 levels are independently prognostic in primary myelofibrosis: A comprehensive cytokine profiling study","author":"Tefferi A","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_10_2","article-title":"DIPSS\u2010Plus: A refined dynamic international prognostic scoring system (DIPSS) for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count and transfusion status","author":"Gangat N","year":"2010","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-223727"},{"key":"e_1_2_5_12_2","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: Therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"Quintas\u2010Cardama A","journal-title":"Blood"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002028"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.8021"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-008-0620-4"},{"key":"e_1_2_5_16_2","article-title":"A phase\u20102 trial of low\u2010dose pomalidomide in myelofibrosis","author":"Begna KH","year":"2010","journal-title":"Leukemia"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21598"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.7356"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.234"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-009746"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.21972","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.21972","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T08:43:18Z","timestamp":1700556198000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.21972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,25]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["10.1002\/ajh.21972"],"URL":"https:\/\/doi.org\/10.1002\/ajh.21972","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,25]]}}}